Search Result Products - CapitalBio Technology Co., Ltd.

All Related Products Other Content

The Disease Susceptibility Genetic Test-High Incidence Cancer (10 Items) This test bases on biochip technology, evaluates the risk of high-incidence cancers from the perspective of genetics, and provide guidance to disease prevention.
Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection As a prenatal screening test, NIPT can determine whether or not a fetus has a chromosomal disorder.
Genetic Testing for Hereditary Breast/Ovarian Cancer(BRCA1/2) This test detects the entire coding region of BRCA1/BRCA2 genes, provides information on preventive guidance、 medication guidance and prognostic assessment.
The Disease Susceptibility Genetic Test-Cancer Screening Package (29 Items) This test is based on biochip technology to evaluate the risk of 29 high-incidence cancers from the perspective of genetics, and provide guidance to disease prevention.
Fetal Chromosomal Aneuploidy and Microdeletions/ Microduplications Detection (NIPT-Plus) NIPT-Plus, an upgraded version of NIPT, can increase birth defect detection from 4% to 34%. It can also detect abnormal trisomy 21, 18 and 13, as well as chromosome micro-deletions and micro-duplicates.
Individualized Medication Guidance for Prostate Cancer This test detects 346 genes, involves targeted therapy, immunotherapy, chemotherapy and hereditary risk assessment, and provides comprehensive medication reference for prostate cancer patients.
The Disease Susceptibility Genetic Test-Anti-Cancer Package A The test is based on biochip technology, by detecting the susceptibility loci on the TP53 gene that are closely related to tumorigenesis, it evaluates its influence on the risk of male tumors and female tumors.
CNV-seq Detection (Semiconductor Sequencing) CNV-Seq technology is capable of analyzing peripheral blood, stream products, fetal tissues, and prenatal diagnostic samples.
Genetic Testing for Blood Cancer This test can detect 232 genes associated with blood cancers, covers all types of leukemia - AML/ALL/CML/CLL/MDS/MPN and various lymphomas.
The Disease Susceptibility Genetic Test-Anti-Cancer Package C This test is based on biochip technology. By detecting TP53, CYP1A1 and XRCC1, assessing their impact on the risk of tumors.
Karyotype Analysis Karyotyping can be used to investigate cytogenetic classification, interspecies relationships, chromosome number and structural variation.
Genetic Testing of 18 Hereditary Cancer This test can provide risk assessment in high-risk groups with a family history by detecting gene mutations in the entire coding region and splice region of 64 genes associated with 18 hereditary tumors at one time.
The Disease Susceptibility Genetic Test-Alzheimer's Disease This test is based on biochip technology to evaluate the risk of Alzheimer's disease by detecting the innate susceptibility genes of the human body.
CMA Detection CMA (Chromosomal Microarray Analysis) is a high-resolution, high-throughput molecular karyotyping technique for detecting copy number variation in human genomic DNA.
Individualized Chemotherapy Drugs For Cancers (10 Genes) This test can detect gene polymorphisms related to 13 common chemotherapeutic drugs, assist clinicians in formulating individualized chemotherapy medication plans.